Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
1(25%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
4
100%

Phase Distribution

0

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution4 total trials
N/ANon-phased studies
4(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(3)

Detailed Status

Completed3
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
N/A

Trials by Phase

N/A4 (100.0%)

Trials by Status

active_not_recruiting125%
completed375%

Recent Activity

1 active trials
Showing 4 of 4
active_not_recruitingnot_applicable

Efficacy of LiveSpo Navax in Supportive Treatment of Pneumonia in Children With RSV and Bacterial Co-infections

NCT05929599
completednot_applicable

LiveSpo Navax® Supports the Treatment of Acute Rhinosinusitis and Otitis Media

NCT05804123
completednot_applicable

Effects of Nasal-spraying LiveSpo Navax in Treatment of Influenza Virus in Children

NCT05378022
completednot_applicable

Effects of Nasal-spraying LiveSpo Navax in Treatment of Acute Respiratory Infections in Children

NCT05164692

Clinical Trials (4)

Showing 4 of 4 trials
NCT05929599Not Applicable

Efficacy of LiveSpo Navax in Supportive Treatment of Pneumonia in Children With RSV and Bacterial Co-infections

Active Not Recruiting
NCT05804123Not Applicable

LiveSpo Navax® Supports the Treatment of Acute Rhinosinusitis and Otitis Media

Completed
NCT05378022Not Applicable

Effects of Nasal-spraying LiveSpo Navax in Treatment of Influenza Virus in Children

Completed
NCT05164692Not Applicable

Effects of Nasal-spraying LiveSpo Navax in Treatment of Acute Respiratory Infections in Children

Completed

All 4 trials loaded

Drug Details

Intervention Type
COMBINATION PRODUCT
Total Trials
4